Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | FLX475 |
| Trade Name | |
| Synonyms | FLX-475|FLX 475 |
| Drug Descriptions |
FLX475 is a CCR4 antagonist, which potentially results in increased effector T-cell and decreased regulatory T-cells within the tumor microenvironment, leading to antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C15724 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| FLX475 | FLX475 | 0 | 1 |
| FLX475 + Ipilimumab | FLX475 Ipilimumab | 0 | 1 |
| FLX475 + Pembrolizumab | FLX475 Pembrolizumab | 0 | 1 |